logo

For the Inventor, By the Inventor

Wuppertal, Germany

Antisense Pharma Gmbh

Calculating rank
USPTO Granted Patents = 10

% Expired Patents = 70.0


Forward Citations = 279

Loading Chart...
Loading Chart...

18 inventors (with patents filed for the assignee):

goldMedal Karl-Hermann Schlingensiepen (6 out of 14 patents)

silverMedal Frank Jaschinski (2 out of 12 patents)

bronzeMedal Anneliese Schneider (2 out of 3 patents)

4.  Mechthild Kunst (2 out of 2 patents)

5.  Reimar Schlingensiepen (2 out of 8 patents)

6.  Anja-Katrin Bosserhoff (1 out of 4 patents)

7.  Andreas Mitsch (1 out of 1 patent)

8.  Bernd Betzler (1 out of 1 patent)

9.  Hubert Heinrichs (1 out of 1 patent)

10.  Susanne Schmaus (1 out of 1 patent)

11.  Tanja Rothammer-Hampl (1 out of 1 patent)

12.  Reinhard Buettner (1 out of 1 patent)

13.  Mara Szyrach (1 out of 1 patent)

14.  Guenter Auerbach (1 out of 1 patent)

15.  Piotr Jachimczak (1 out of 1 patent)


10 patents:

1. 8936910 - Method for selective oligonucleotide modification (2015-01-20),
2. 8822425 - Dosage of oligonucleotides suitable for the treatment of tumors (2014-09-02),
3. D709183 - Pump for pharmaceutical and cosmetic products (2014-07-15),
4. D697204 - Pump for pharmaceutical and cosmetics products (2014-01-07),
5. 8476246 - Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system (2013-07-02),
6. 8177775 - Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique (2012-05-15),
7. 8148493 - Method for inhibiting 'melanoma inhibitory activity' MIA (2012-04-03),
8. 8097597 - Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors (2012-01-17),
9. 7963956 - Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique (2011-06-21),
10. 7910563 - Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA (2011-03-22),
Company Overview
Antisense Pharma GmbH, based in Wuppertal, Germany, specializes in the development of innovative therapies utilizing antisense oligonucleotide technology. The company focuses on addressing unmet medical needs in various therapeutic areas, particularly in oncology and rare diseases. By leveraging its expertise in molecular biology and drug development, Antisense Pharma aims to create targeted treatments that can effectively modulate gene expression, offering new hope for patients with challenging health conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

10 Patents

#39 in Wuppertal

#3,764 in Germany

#56,228 in the World

Wuppertal, DE
Wuppertal, Germany

Antisense Pharma Gmbh

Forward Citations = 279

18 inventors:

goldMedal Karl-Hermann Schlingensiepen (6 out of 14 patents)

silverMedal Frank Jaschinski (2 out of 12 patents)

bronzeMedal Anneliese Schneider (2 out of 3 patents)

4.  Mechthild Kunst (2 out of 2 patents)

5.  Reimar Schlingensiepen (2 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Antisense Pharma Gmbh. Retrieved from https://idiyas.com/company/antisense-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…